BioSyent Announces Appointment of New Director
January 16 2014 - 8:00AM
Marketwired
BioSyent Announces Appointment of New Director
TORONTO, ONTARIO--(Marketwired - Jan 16, 2014) - The Board of
Directors of BioSyent Inc. ("BioSyent") (TSX-VENTURE:RX) is pleased
to announce the appointment of Stephen Wilton to the Company's
Board.
Mr. Wilton brings to BioSyent over 28 years of experience in the
pharmaceutical industry. A licensed pharmacist, Mr. Wilton earned a
B.Sc. in Pharmacy from the University of Toronto and started his
career working as a pharmacist in community and hospital pharmacy.
After working in medical sales and marketing positions at Eli Lilly
Canada he joined AstraZeneca Canada where he enjoyed a long and
varied career. While at AstraZeneca, Mr. Wilton held leadership
positions in Marketing where as Executive Director he led a team
managing a $300 million specialty product portfolio, as well as
three other assignments as Executive Director of Business
Development, Executive Director of Pricing, Reimbursment and
Healthcare Solutions, and Director of Regulatory Affairs.
After his 17 year career at AstraZeneca, Mr. Wilton worked as
Vice President of Pharmacy Affairs for the Canadian Association of
Chain Drug Stores representing the interests of owners and
pharmacists in the Canadian healthcare system.
Mr. Wilton, who also holds an MBA from York University (Schulich
School of Business) is presently President at Market Access
Investment Advisors Inc.
BioSyent Inc. also announces the grant of 22,455 incentive stock
options to certain employees, officers and Directors of the
Company. These incentive stock options are excercisable at a price
of $4.45 up to January 14, 2019.
For a direct market quote (15 minutes delay) for the TSX Venture
Exchange and other Company financial information please visit
www.tmxmoney.com.
About BioSyent Inc.
Listed on the Toronto Venture Exchange under the trading symbol
"RX", BioSyent is a profitable growth oriented specialty
pharmaceutical company which searches the globe to in-license or
acquire innovative pharmaceutical products that have been
successfully developed, are safe and effective, and have a proven
track record of improving the lives of patients and supporting the
healthcare professionals that treat them.
Once a product of interest has been found, BioSyent then
acquires the exclusive rights to the product and manages it through
the Canadian governmental regulatory approval process. Once
approved, BioSyent markets the product throughout Canada.
At the date of this press release the Company had 13,626,195
shares issued and outstanding.
This press release may contain information or statements that
are forward-looking. The contents herein represent our judgment, as
at the release date, and are subject to risks and uncertainties
that may cause actual results or outcomes to be materially
different from the forward-looking information or statements.
Potential risks may include, but are not limited to, those
associated with clinical trials, product development, future
revenue, operations, profitability and obtaining regulatory
approvals.
The TSX Venture Exchange assumes no responsibility for the
accuracy of this release and neither approves nor disapproves of
the same.
BioSyent Inc.Mr. Rene C. GoehrumPresident and CEO(905)
206-0013investors@biosyent.comwww.biosyent.com
Biosyent (TSXV:RX)
Historical Stock Chart
From May 2024 to Jun 2024
Biosyent (TSXV:RX)
Historical Stock Chart
From Jun 2023 to Jun 2024